Suppr超能文献

兔急性心肌梗死期间,艾卡苷未能限制梗死面积。

Failure of AICA riboside to limit infarct size during acute myocardial infarction in rabbits.

作者信息

Dorion M, Rouleau J, Kingma J G

机构信息

Department of Medicine, Faculty of Medicine, Laval University, Ste-Foy, Quebec, Canada.

出版信息

J Cardiovasc Pharmacol. 1992 Jan;19(1):69-77. doi: 10.1097/00005344-199201000-00010.

Abstract

This study examined whether the adenosine potentiator, 5-aminoimidazole-4-carboxamide riboside (AICAr), could limit tissue necrosis during acute myocardial infarction in rabbit hearts with minimal coronary collateral flow. Forty-four rabbits underwent 45 min of ischemia with or without coronary reperfusion for 180 min. Five groups were studied. Saline or AICAr (20 mg/kg, i.v.) was administered as a bolus either 10 min before coronary occlusion or 10 min before the onset of coronary reperfusion. The anatomic risk zone size was assessed by radiolabeled microsphere autoradiography and the area of tissue necrosis was defined using the tetrazolium staining method. Coronary collateral flow in the central ischemic zone was assessed using the radiolabeled microsphere technique. No differences were observed for tissue necrosis (normalized to risk zone size) for saline- and AICAr-treated rabbits (66.2 +/- 10.9% vs. 70.8 +/- 19.9%, p = NS) subjected to 45 min of coronary occlusion without reperfusion. Similarly, tissue necrosis in rabbit hearts with 45 min of coronary occlusion followed by 180 min of reperfusion was not significantly reduced when AICAr was administered either 10 min before ischemia or 10 min before reperfusion (79.8 +/- 17.5 and 76.4 +/- 8.1%, respectively) compared to saline-treated controls (68.1 +/- 22.7%). Coronary collateral flow in these hearts was almost nonexistent. The risk zone size and cardiac hemodynamics were similar between the treatment groups. These results demonstrate that AICAr was unable to limit myocyte necrosis when administered either before ischemia or before coronary reperfusion in this experimental preparation of acute myocardial infarction.

摘要

本研究探讨了腺苷增强剂5-氨基咪唑-4-甲酰胺核苷(AICAr)能否在冠状动脉侧支血流极少的兔急性心肌梗死过程中限制组织坏死。44只兔子经历了45分钟的缺血,伴有或不伴有180分钟的冠状动脉再灌注。研究分为五组。在冠状动脉闭塞前10分钟或冠状动脉再灌注开始前10分钟静脉推注生理盐水或AICAr(20mg/kg)。通过放射性微球放射自显影评估解剖学风险区大小,并使用四氮唑染色法确定组织坏死面积。采用放射性微球技术评估中心缺血区的冠状动脉侧支血流。在未进行再灌注的情况下,接受45分钟冠状动脉闭塞的生理盐水组和AICAr组兔子的组织坏死情况(相对于风险区大小进行标准化)无差异(分别为66.2±10.9%和70.8±19.9%,p=无显著性差异)。同样,在冠状动脉闭塞45分钟后再灌注180分钟的兔心脏中,与生理盐水处理的对照组(68.1±22.7%)相比,在缺血前10分钟或再灌注前10分钟给予AICAr时,组织坏死并未显著减少(分别为79.8±17.5%和76.4±8.1%)。这些心脏的冠状动脉侧支血流几乎不存在。各治疗组之间的风险区大小和心脏血流动力学相似。这些结果表明,在该急性心肌梗死实验制剂中,在缺血前或冠状动脉再灌注前给予AICAr无法限制心肌细胞坏死。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验